- Home
- ADC vs ARWR Comparison
ADC vs ARWR Comparison
Compare ADC & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADC | ARWR |
|---|---|---|
| Founded | 1971 | 2003 |
| Country | United States | United States |
| Employees | 90 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 10.2B |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | ADC | ARWR |
|---|---|---|
| Price | $77.84 | $76.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | ★ $84.50 | $83.40 |
| AVG Volume (30 Days) | 1.1M | ★ 1.9M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $12.01 | N/A |
| Revenue Next Year | $9.90 | N/A |
| P/E Ratio | $43.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $69.56 | $14.30 |
| 52 Week High | $82.08 | $87.83 |
Technical Indicators
Market Signals| Indicator | ADC | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 59.79 | 44.18 |
| Support Level | $70.41 | $70.05 |
| Resistance Level | $80.02 | $77.39 |
| Average True Range (ATR) | 0.98 | 4.15 |
| MACD | 0.28 | -0.17 |
| Stochastic Oscillator | 75.40 | 5.36 |
Price Performance
Historical ComparisonAbout ADC Agree Realty Corporation
Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-tenants. The Company is mainly in the business of acquiring, developing and managing retail real estate. Some of its properties in the portfolio include Walmart, 7-Eleven, Wawa, Gerber Collision and others.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.